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University Hospital, Nashville, Tennessee 37232, USA
Fetal heart rate (F.H.R.) variability has been
recognized for many years äs a useful guide in
assessing fetal well being [4]. While normal fetal
heart rate variability is associated with fetal health,
a loss of this variability, especially when associated
withlate decelerationorsevere variable deceleration
patterns, has been shown to be an omnious sign of
fetal distress [2]. Since drugs such äs meperidine,
propiomazine and scopolamine often result in
a loss of fetal heart rate variability [1], secondary
to their central autonomic suppression, this
Parameter of fetal heart rate monitoring often
cannot be assessed accurately when these drugs
are present in the patient in labor. Because of this,
it might be beneflcial to attempt to reverse this
drug induced loss of fetal heart rate variability if,
during labor, confusion arose äs to its importance
in assessing fetal distress. Since physostigmine can
be used to reverse the delirium resulting when
scopolamine is given to an adult [3] and since it is
a drug well known for its anticholinesterase activity,
physostigmine was given to patients in labor
previously given scopolamine alone and meperidine
and propiomazine in combination to ascertain the
effect on reversing the loss of fetal heart rate
variability caused by the administration of these
drugs.
Materials and methods
Seventeen healthy women between 39 and 42 weeks
gestation in early labor who had received no
medication previously were utilized for this
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study. The age ränge of the patients studied was
15 to 33 while parity and ränge was 0 to 3. Patients
were screened for allergies to drugs äs well äs
history of asthma because of physostigmine's
Potential adverse effect in patients with these
Problems. Internal fetal heart rate monitoring
was accomplished by the use of a scalp electrode
attached to a fetal monitor* after artificial or
spontaneous rupture of the amniotic-membranes.
Maternal blood pressure and pulse were recorded
at two minute intervals and base line fetal heart
rate variability was recorded and classified äs
previously described [1]. All patients were noted
* Corometrics - Wallingford, Conn.
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to display normal fetal heart rate variability prior
to drug administration. Total scopolamine doses
of 0.65 to 1.08 mgs was given intravenously to 7
patients followed by 2 to 5 mgs of physostigmine
intravenously after establishing a decrease of fetal
heart rate variability. This same procedure was
foUowed in 10 patients after administration of
meperidine, 50 mgs, and propiomazine, 20 mgs,
intravenously. Maternal blood pressure, pulse, äs
well äs fetal heart rate variability was then assessed
for 60 minutes following the infusion of physo-
stigmine.
Results
Scopolamine in doses of 0.65 to l .08 mgs diminished
fetal heart rate variability in all 7 patients and
physostigmine reversed this loss of fetal heart rate
variability in all 7 patients within 4 to 17 minutes
(average 9 min.) (Tab. I, Figs. 1-3). No remark-
able maternal blood pressure changes were recorded
.after administration of physostigmine in the 7
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Fig. 1. Fetal heart rate tracing revealing normal variabüity prior to scopolomine infusion.
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Fig. 2. Fetal heart rate tracing revealing loss of variability after scopolomine infusion.
Fig. 3. Fetal heart rate tracing revealing abrupt return to normal variability 11 minutes after infusion of the first 2 mg
dose of physostigmine.
patients studied although l patient did sustain an
elevation of 40 mm Hg in systolic pressure which
returned to the base line within 14 minutes (Fig. 4).
Maternal pulse rate, already elevated sligh y by
scopolamine, was reduced to 56obeats per minute
in l patient (Fig. 4). No adverse systemic reactions
to either scopolamine or physostigmine was noted
in any of the patients. Fetal scalp samples obtained
within 10 minutes after physostigmine administra-
tion was performed in 2 patients and were found
to be within normal limits, however no further
attempts were made to follow fetal scalp pH because
of fetal manipulation effects on fetal heart rate
variability. No pathological fetal heart rate patterns
J. Perinat. Med. 5 (1977)
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PATIENT NO: 5
MATERNAL B P (blood pressure) and P R (pulse rate) changes related in TIME following physostigmine admimstration.
X : B P (systolic)
+ : B P (diastolic)
0 : P R (pulse rate)
(1) : following the first dose of physostigmine of 2 mg., intravenously.
(2): after the second dose of physostigmine of 2 mg., intravenously.
Fig. 4. Graph depicting a rise in systolic blood pressure and a fall in maternal pulse rate.
or significant fetal heart rate base line changes
were recorded during the study. All patients
delivered normal term neonates with 5 minute»
Apgar scores of 8,9 or 10.
The 10 patients who were given meperidine and
propiomazine whose fetal heart rate variability was
diminished sufficient to ascertain physostigmine's
effect were noted to show an increase in fetal
heart rate base line variability within 3 to 17
minutes (average 9.1 min.) after the administration
of 3—4 mgs of physostigmine intravenously
(Tab. I, Figs. 5-10). While one patient's pulse
decreased 40 beats per minute within 5 minutes
of physostigmine's infusion, no patient's pulse
rate feil below 60 beats per minute. Most pulse
rates remained stable, feil slighfly, or occasionally
J. Perinat. Med. 5(1977)
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Figs. 5 & 6. Fetal heart rate tracings revealing normal variability prior to meperidine and propiomazine infusions.
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Figs. 7 & 8. Fetal heart rate tracings revealing loss of variab ity after administration of meperidine and propiomazine.
J. Perinat. Med. 5 (1977)
220 Boehm et al., Drug effect on fetal heart rate variability
• ι . · «. ,.ι τ ι. ,„.,..,—..n _^i „..— ' - ..*_·.-. .. ,. .ϊ . t.^.^.^1 ,ivf .rr\--.t e..i · y-"T F , - . 7 r n-i-f.i '?t~*\<f'^ίιη.ί-.ίΊι.ιι- - ^i*,ij7>? j;. ; , j r- i j j f · : -r^-j τ -t»'--· ·"· "ji




Figs. 9 & 10. Fetal heart rate tracings revealing abrupt return to normal variability minutes after physostigmine inf sion.
were noted to be elevated following physostigmine
inf sion. There were no significant blood pressure
changes recorded in this group of patients. Again,
no pathological fetal heart rate patterns were
recorded any time during the study and all patients
delivered normal term neonates with 5 minute
Apgar scores of 8,9 or 10.
Comments
Physostigmine, an anticholinesterase drug and
capable of crossing the blood brain barrier, has
been noted to be able to reverse the delirium
produced by atropine like drugs [3]. Its effect,
however, on fetal heart rate variability has not
been previously studied. It seems tenable from
this study that physostigmine does cross the
placental barrier and enters the fetal circulation
and that this usually occurs within 3 to 17 minutes
with an average of approximately 9 minutes. The
possibility of utilizing this drug to determine
placental functionin the future is intriguing. In the
healthy fetus the loss of fetal heart rate variability
caused by scopolamine, meperidine orpropiomazine
can be reversed by the use of physostigmine and
thisreversal seems abrupt and clinically measurable
on the fetal monitor print out. Matemal responses
to blood pressure and pulse after inf sion.of
physostigmine are minimal and are in agreement
with other studies. SMILER, et al. recorded no
adverse effects of physostigmine in doses of 3 mg
intravenously on the fetus or mother and noted no
fetal or maternal bradycardia [3], Matemal br dy-
cardia (less than 50 beats per minute) was not
J. Perinat. Med. 5 (1977)
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noted in any of our patients studied, however,
one was noted to have a pulse rate of 56 beats
per minute. This patient was given a total of 4 mg
of physostigmine. The fact that physostigmine can
reverse the loss of fetal heart rate variability caused
by meperidine and propiomazine support the fact
that such depression of fetal heart rate variability
caused by these drugs may be based on their
atropine like properties.
Studies to ascertain physostigmine's effect on fetal
heart rate variability in animals who are noted to
display loss of fetal heart rate variability secondary
to induced fetal distress will need to be performed
in the future" If no such retum of fetal heart rate
variability is noted in this experimental Situation it
wouldseem tenable to use the drug, physostigmine,
äs a clinical test to distinguish the fetus in distress
from one whose fetal heart rate variability is dimin-
ished secondary to drug administration. Therefore,
in the sedated patient who displays a questionable
pathological fetal heart rate deceleration, a quick
return to normal variability after administration of
physostigmine, might obviate the need for fetal
scalp sampling or other obstetrical Intervention.
Because physostigmine might cause further phys-
iological embarrassment in the already acidotic or
hypoxic Situation, human use to differentiate
fetal distress from drug effect is not recommended
until further studies have clarified this possibility.
Summary
Physostigmine was given to 17 patients in labor, previously
given scopolamine alone or meperidine and propiomazine
in combination, to ascertain its effect on reversing the loss
of fetal heart rate variability caused by the administration
of these drugs. The results of the study indicated that
scopolamine indosesof 0.65 to 1.08 milligrams diminished
fetal heart rate variability in all 7 patients and physostig-
mine reversed this loss of fetal heart rate variability in all
7 patients within 4 to 17 minutes after injection of the
first dose of physostigmine. Similar results were noted in
10 patients with the combination of meperidine, 50 mg,
and propiomazine, 20 mg. It seems tenable from this study
that physostigmine does cross the placental barrier and
enters the fetal circulation and that this usually occurs
within 3 to 17 minutes with an average of approximately
9 minutes. In the healthy fetus the loss of fetal heart rate
variability caused by scopolamine, meperidine or propio-
mazine can be reversed by the use of physostigmine and
this reversal seems abrupt and clinically measurable on
the fetal monitor print out.
Keywords: Anticholinesterase, fetal distress, monitoring, physostigmine, placental barrier, variability.
Zusammenfassung
Der Einfluß von Physostigmin auf die durch Scopolamin-,
Meperidin- und Propiomazininduzierte Verminderung der
Schlag-zu-Schlag-Variabilität der FHF
Bei 17 Patientinnen, die kurz zuvor Scopolamin alleine
oder Meperidin oder Propiomazin zusammen erhalten
hatten, wurde subpartualPhysostigmin\gegeben.,Zierwar!es,
den Neutralisationseffekt auf den Fluktuationsverlust der
FHF, der durch Applikation der genannten Medikamente
ausgelöst worden war, zu sichern. Die Resultate dieser
Untersuchung zeigen, daß Scopolamin in einer Dosierung
von 0,65 bis 1,08 mg bei allen 7 Patientinnen die Schlag-
zu-Schlag-Variabilität negativ beeinflußte und das
Physostigmin diesen Fluktuationsverlust der FHF bei
allen 7 Patientinnen innerhalb von 4-17 Min. nach In-
jektion der 1. Dosis aufzuheben imstande war. Analoge
Resultate konnten bei 10 Patientinnen, die Meperidin
50 mg und Propiomazin 20 mg erhalten hatten, beob-
achtet werden. Es scheint auf Grund dieser Untersuchun-
gen erwiesen, daß Physostigmin die Plazentaschranke
passiert und in den fetalen Kreislauf übertritt; dies ge-
schieht in der Regel innerhalb von 3-17 Minuten, wobei
der Mittelwert ungefähr 9 Min. beträgt. Der durch
Scopolamin, Meperidin und Propiomazin hervorgerufene
Fluktuationsverlust der FHF kann beim gesunden Fetus
durch Gabe von Physostigmin aufgehoben werden; diese
Wiederherstellung erfolgt rasch und kann klinisch auf
den Kardiotokogrammen dokumentiert werden.
Schlüsselwörter: Anticholinesterase, fetal distress, FHF-Überwachung, Physostigmin, Placenta-Schranke, Schlag-zu-
Schlag-Variabilität.
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Resume
Effet de la physostigmine sur la baisse de variab ite de la
frequence cardiaque foetale causee par la scopolamine, la
meperidine et la propiomazine
17 malades trait6s cn laboratoire avaient Γβςιι de la
scopolamine seule ου un melange dose de meperidine et
de propiomazine, a la suite de quoi on leur a administre
de la physostigmine pour observer ses effets sur le
revirement deperte de variabilite de la frequence cardiaque
foetale causee par la prise des medicaments precites. Les
resultats des examens ont montre que la scopolamine
appliquee a doses de 0,65 1,08 milligrammes fait baisser
la variabilite de la frequence cardiaque foetale chez les 7
malades et que la physostigmine a renverse cette baisse
chez les 7 patientes dans l' space de 4 a 17 minutes apres
Tinjection de la premiere dose de physostigmine. Des
resultats sim aiies ont ete observes chez les 10 malades
ayant regu un melange de 50 mg de meperidine et de
20 mg de propiomazine. Cette etude laisse supposer que
la physostigmine traverse la barriere placentaire pour pene-
trer dans la ciiculation foetale et cela, generalement, entre
3 et 17 minutes, la moyenne etant de 9 minutes environ.
Chez le f oetus sain, la perte de variabilite de la frequence
cardiaque foetale, causee par la scopolamine, la meperidine
ou la propiomazine, peut etre renversee par ladministration
de physostigmine, et ce revirement semble s'operer de
facon assez brusque et peut etre mesure cliniquement sur
l'enregistrement par moniteur du foetus.
Mots-cles: anticholinesterase, barriere placentaire, distress foetal, monitoring, physostigmine, variabilite
Bibliography
[l] BOEHM, F. H., J. H. GROWDON: The effect of
scopolamine on fetal heart rate base line variability.
Am. J. Obstet. Gynecol. 120 (1974) 1099
[2] PAUL, R. H., E. H. HON: Clinical fetal monitoring.
A survey of current usage. Obstet. Gynecol. 37
(1971)779
[3] SMILER,B.G.,E.G. BARTHOLOMEW, B. J. SIVAX:
Physostigmine reversal of scopolamine delirium in
obstetric patient. Am. J. Obstet. Gynecol. 116 (1973)
326
[41 YEH,S-Y.,A.FORSYTHE,E.H.HON: Quantification
of fetal heart beat-to-beat interval differences. Obstet.
Gynecol. 41 (1973)355
Received January 8, 1977. Accepted March 24, 1977.
Frank H. Boehm, M.D.
Associate Professor
Department of Obstetrics and Gynecology
Vanderbilt University Hospital
21 st. Avenue, South
Nashville, Tennessee 37232, USA
J. Perinat. Med. 5 (1977)
